Shortage of Menopur (menotropin)  
Powder and solvent for solution for injection

### Indication
Menopur is used to treat female and male infertility.

### Reason for shortage
In October 2022, the marketing authorisation holder, Ferring, suspended supply of Menopur (all presentations). This was a precautionary measure after the company had been made aware of unapproved changes in the manufacturing process of the active substance of Menopur. As a result, supplies of all presentations are constrained in EU Member States. The data available to date do not indicate any immediate safety issue due to the changes in the manufacturing process.

### Member States affected
Menopur has been or may be temporarily suspended in the following EU Member States: Austria, Bulgaria, Croatia, Cyprus, Czechia, Greece, Hungary, Italy, Poland, Portugal, Romania, Slovakia, Slovenia, and Spain. Shortages are possible in all other EU Member States where the product continues to be marketed.

### Monitoring of shortage
EMA’s SPOC working party is closely monitoring the supply situation and engaging with Ferring to obtain the necessary approvals and resume supply. The SPOC working party is also meeting with manufacturers of alternative medicines to ensure patients can continue to be treated.

The SPOC working party is responsible for monitoring and reporting events that could affect the supply of medicines in the EU. Summaries of the SPOC working party meetings can be found on EMA’s website.

### Information for healthcare professionals
- All shipments of Menopur were temporarily suspended which resulted in a shortage of the medicine that may continue through 2025 in some EU countries.
- In view of the lack of alternatives in several Member States, Menopur

---

1 This document was first published on 3 April 2023. It was modified on 21 April to reflect the updated supply situation at the time. It was further modified on 8 July 2024 to reflect the updated timelines for the shortage.
2 This information may change. For up-to-date information about the status of a medicine shortage in a particular Member State, consult the national shortage register or contact the national competent authority.
### Shortage of Menopur (menotropin)
**Powder and solvent for solution for injection**

| manufactured with unapproved changes may continue to be supplied and used, based on national decision. |
| In Member States where Menopur is no longer available, alternatives should be used. |
| A direct healthcare professional communication (DHPC) has been sent to healthcare professionals where needed and is published on the [EMA website](https://www.ema.europa.eu). |
| For additional information consult your country’s [shortage register](https://www.ema.europa.eu) or contact your [national competent authority](https://www.ema.europa.eu). |

### Information for patients

- All shipments of Menopur were temporarily suspended which resulted in a shortage of the medicine which may continue through 2025 in some EU countries.
- In view of the lack of alternatives in several Member States, Menopur manufactured with unapproved changes may continue to be supplied and used based on national decision.
- In Member States where Menopur is no longer available, alternatives should be used in consultation with a healthcare professional.
- Patients who have any questions should speak to their doctor or pharmacist.
- For additional information consult your country’s [shortage register](https://www.ema.europa.eu) or contact your [national competent authority](https://www.ema.europa.eu).

### Status

Ongoing